deltatrials
Active Not Recruiting PHASE3 INTERVENTIONAL 3-arm NCT02475681

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL (ElevateTN)

A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, Acalabrutinib (ACP-196) in Combination With Obinutuzumab, and Acalabrutinib Monotherapy in Subjects With Previously Untreated CLL

Sponsor: Acerta Pharma BV

Conditions Chronic Lymphocytic Leukemia
Interventions Acalabrutinib Chlorambucil Obinutuzumab
Updated 21 times since 2017 Last updated: Aug 26, 2025 Started: Jun 26, 2015 Primary completion: Feb 8, 2019 Completion: Sep 30, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Chronic Lymphocytic Leukemia and is currently ongoing. Acerta Pharma BV leads this study, which shows 21 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Jun 2018 · 12 months · monthly snapshot~Jun 2018 – ~Sep 2019 · 15 months · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Jan 2021 · 14 months · monthly snapshot~Jan 2021 – ~Nov 2021 · 10 months · monthly snapshot~Nov 2021 – ~Feb 2023 · 15 months · monthly snapshot~Feb 2023 – ~Apr 2023 · 59 days · monthly snapshot~Apr 2023 – ~Sep 2023 · 5 months · monthly snapshot~Sep 2023 – ~Dec 2023 · 3 months · monthly snapshot~Dec 2023 – ~Apr 2024 · 4 months · monthly snapshot~Apr 2024 – ~Jun 2024 · 2 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Jan 2025 · 3 months · monthly snapshot~Jan 2025 – ~Apr 2025 · 3 months · monthly snapshot~Apr 2025 – ~Jul 2025 · 3 months · monthly snapshot~Jul 2025 – ~Sep 2025 · 2 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

21 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE3

  2. Jul 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE3

  3. Apr 2025 — Jul 2025 [monthly]

    Active Not Recruiting PHASE3

  4. Jan 2025 — Apr 2025 [monthly]

    Active Not Recruiting PHASE3

  5. Oct 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE3

▶ Show 16 earlier versions

  1. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  3. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  4. Apr 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE3

  5. Dec 2023 — Apr 2024 [monthly]

    Active Not Recruiting PHASE3

  6. Sep 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE3

  7. Apr 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE3

  8. Feb 2023 — Apr 2023 [monthly]

    Active Not Recruiting PHASE3

    Status: Unknown Status → Active Not Recruiting

  9. Nov 2021 — Feb 2023 [monthly]

    Unknown Status PHASE3

    Status: Active Not Recruiting → Unknown Status

  10. Jan 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE3

  11. Nov 2019 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  12. Sep 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE3

  13. Jun 2018 — Sep 2019 [monthly]

    Active Not Recruiting PHASE3

  14. Jun 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  15. Feb 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  16. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Jun 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Acerta Pharma BV
Data source: Acerta Pharma BV

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alessandria, Italy , Anaheim, United States , Aschaffenburg, Germany , Ashkelon, Israel , Auckland, New Zealand , Aurora, United States , Austin, United States , Aviano, Italy , Barcelona, Spain , Barretos, Brazil and 133 more locations